CAMBRIDGE, Mass., Oct. 17, 2017 /PRNewswire/ -- Goldfinch Bio, a company singularly focused on discovering and developingprecision therapies to treat patients with kidney disease, today announced collaborations with the Icahn School of Medicine at Mount Sinai and Vanderbilt University Medical Center to generate genomic data on over 1,500 patients
Goldfinch Bio is leading a new age of therapeutic discovery and development in the kidney space, and is building the world's largest genomic registry of patients with kidney disease to inform new disease targets, pathways, and biomarkers for the discovery and development of novel therapies. The patient registry is a key component of the company's integrated product engine, which will drive breakthroughs in genetics and biology to bring precision medicines to patients with kidney disease.
In October 2017, Goldfinch announced the Company's foundational patient registry collaboration with The Nephrotic Syndrome Study Network (NEPTUNE), a network of academic centers focused on clinical and translational research on kidney diseases presenting as Nephrotic Syndrome. The collaborations with Mount Sinai and Vanderbilt University Medical Center build upon this foundation, creating a comprehensive, federated database that integrates patient clinical data with molecular characterization at the DNA, RNA, and protein level.
"We are thrilled to work with the Icahn School of Medicine at Mount Sinai and Vanderbilt University Medical Center to advance our understanding of the molecular pathways of kidney disease and bring precision medicines to patients," stated Abbie Celniker, Ph.D., interim chief executive officer of Goldfinch.
About Goldfinch BioGoldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney disease. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for people with kidney disease. Goldfinch was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass. For more information, please visit www.goldfinchbio.com.
Goldfinch Bio ContactJennifer WilliamsCook Williams Communications, [email protected]360-668-3701
View original content:http://www.prnewswire.com/news-releases/goldfinch-bio-announces-collaborations-with-icahn-school-of-medicine-at-mount-sinai-and-vanderbilt-university-medical-center-to-augment-worlds-largest-genomic-registry-of-patients-with-kidney-disease-300536682.html
SOURCE Goldfinch Bio
Subscribe to our Free Newsletters!
Opportunistic infections are microbial infections that can cause disease in persons with a weak ...
The state health insurance programs provide health care support to the below poverty line (BPL) ...
There is a lining between the lungs and chest wall known as Pleura. The dismissal of pleura by a ...View All